Management of Bronchiolitis in Infants
Core Principle: Supportive Care Only
Bronchiolitis management is entirely supportive—do not routinely use bronchodilators, corticosteroids, antibiotics, or ribavirin in most cases. 1
The 2014 AAP guidelines establish that supportive care is the mainstay of treatment, with most pharmacologic interventions showing no benefit and potential harm. 1, 2
Diagnosis
Clinical Assessment
- Diagnose bronchiolitis based on history and physical examination alone—do not obtain routine radiographic or laboratory studies. 1
- Key clinical features include: viral upper respiratory prodrome followed by tachypnea, wheezing, rales, retractions, nasal flaring, and grunting. 1
- Count respiratory rate over a full minute for accuracy (50th percentile: 41 breaths/min at 0-3 months, declining to 31 breaths/min at 12-18 months). 1
RSV Testing
- RSV testing may be useful to reduce hospital transmission but is not required for clinical management in most cases. 3
- If considering ribavirin (see below), RSV must be documented by rapid diagnostic methods (immunofluorescence or ELISA) before or within 24 hours of treatment. 4
Risk Stratification
Assess for risk factors that predict severe disease: 1
- Age <12 weeks
- Prematurity
- Hemodynamically significant congenital heart disease
- Chronic lung disease (bronchopulmonary dysplasia)
- Immunodeficiency
- Neuromuscular disease, cystic fibrosis, Down syndrome 2
These infants require more careful evaluation and lower thresholds for hospitalization. 1, 3
Hospitalization Criteria
Admit infants who meet any of the following: 3
- Oxygen saturation <90-92%
- Moderate-to-severe respiratory distress
- Dehydration or inability to maintain oral intake
- Presence of apnea
- Presence of high-risk conditions listed above 3, 2
Supportive Care Interventions
Oxygen Therapy
- Provide humidified supplemental oxygen to maintain saturation ≥90-92%. 3, 5
- Oxygen administration is one of only two interventions proven reliably beneficial. 6
Hydration and Nutrition
- Ensure adequate fluid replacement through oral, nasogastric, or intravenous routes as needed. 3, 5, 6
- Judicious fluid management is the second proven beneficial intervention. 6
Airway Clearance
- Perform nasal suctioning to reduce upper airway obstruction and improve work of breathing. 1, 3
- Positioning may also decrease work of breathing. 1
Hypertonic Saline
- Nebulized 3% hypertonic saline may decrease length of hospital stay when administered with a bronchodilator. 5
- Some evidence supports its use as part of supportive care. 3, 7
Pharmacologic Interventions: What NOT to Use
Bronchodilators (Albuterol/Salbutamol)
- Do not routinely use bronchodilators—evidence shows no benefit with potential risk of harm. 2
- The 2014 AAP guidelines deimplemented routine albuterol use. 1, 8
- Exception: Some recent meta-analyses suggest therapeutic trials in the outpatient setting may benefit select patients, but this remains controversial. 8
Nebulized Epinephrine
- Do not use routinely. 1
- May have a small short-term effect in the emergency department setting for symptom relief. 3, 5
- Can be considered for treatment as needed in hospital settings, but not as routine therapy. 3
Corticosteroids
- Do not use systemic or inhaled corticosteroids—no evidence of benefit. 2, 5, 6
- Even in infants with atopic phenotypes or family history of atopy, corticosteroids do not reduce length of stay or oxygen requirements. 9
Antibiotics
- Do not use antibiotics routinely—bronchiolitis is viral and antibiotics show no benefit with potential harm. 2, 5
- Reserve antibiotics only for documented bacterial co-infection. 9
- Inappropriate antibiotic use is associated with longer hospital stays. 9
Ribavirin
- Ribavirin is indicated ONLY for severe RSV bronchiolitis in hospitalized infants with documented RSV infection. 4
- FDA labeling specifies use for severe lower respiratory tract RSV infections, particularly in high-risk patients (prematurity, immunosuppression, cardiopulmonary disease). 4
- Treatment should be initiated early (within first 3 days of illness) and only continued with documented RSV. 4
- In mechanically ventilated infants, ribavirin significantly decreased duration of mechanical ventilation (4.9 vs 9.9 days, p=0.01) and supplemental oxygen (8.7 vs 13.5 days, p=0.01). 4
- However, current guidelines do not recommend routine use due to limited evidence of clinical benefit, cost, and practical administration challenges. 5, 6
Other Ineffective Therapies
- Ipratropium: no benefit 5
- Montelukast: no benefit 5
- RSV immunoglobulin for treatment: no benefit 5
- Chest physiotherapy: no benefit 3, 5
- Nebulized deoxyribonuclease: no benefit 5
Prevention: Palivizumab Prophylaxis
Palivizumab (anti-RSV monoclonal antibody) is indicated for specific high-risk categories during RSV epidemic season: 3, 7, 5
- Premature infants
- Infants with bronchopulmonary dysplasia
- Infants with hemodynamically significant congenital heart disease
- Other high-risk conditions as defined by current AAP recommendations
Palivizumab can decrease disease severity and hospitalization rates in these populations. 5
Intensive Care Considerations
Mechanical Ventilation
- Required in approximately 4% of hospitalized infants. 10
- Use of ribavirin in mechanically ventilated patients should only be undertaken by physicians familiar with this mode of administration. 4
Adjuvant Therapies for Severe Disease
- Exogenous surfactant and helium/oxygen mixtures (heliox) have been suggested in small studies for severe disease but lack robust evidence. 6
- Combination therapies aimed at relieving airway obstruction may offer benefit when administered very early or to infants with more severe disease. 6
Common Pitfalls to Avoid
Over-testing: Do not routinely order chest X-rays, viral panels beyond RSV (unless needed for infection control), or blood work. 1
Inappropriate medication use: The vast majority of bronchiolitis is mild and self-limited—resist pressure to prescribe bronchodilators, steroids, or antibiotics. 4, 2, 10
Delayed recognition of severe disease: Serial observations may be needed as bronchiolitis has a variable and dynamic course. 1
Ignoring risk factors: Infants with underlying conditions require lower thresholds for intervention and admission. 1, 3
Misuse of ribavirin: Only consider in severe, documented RSV cases in high-risk hospitalized infants—not for routine or mild disease. 4
Quality Improvement
Recent data demonstrate that structured educational interventions, internal monitoring, and audit-feedback strategies effectively reduce non-evidence-based prescribing (bronchodilators, steroids, antibiotics) and improve adherence to supportive care guidelines. 10 De-implementation of ineffective therapies should be a major institutional goal. 2, 10